These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28131197)

  • 21. Impact of inability to turn in bed assessed by a wearable three-axis accelerometer on patients with Parkinson's disease.
    Uchino K; Shiraishi M; Tanaka K; Akamatsu M; Hasegawa Y
    PLoS One; 2017; 12(11):e0187616. PubMed ID: 29121638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease is associated with greater regularity of repetitive voluntary movements.
    Powell DW; Muthumani A; Xia R
    Motor Control; 2014 Jul; 18(3):263-77. PubMed ID: 24457290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring.
    van Hilten B; Hoff JI; Middelkoop HA; van der Velde EA; Kerkhof GA; Wauquier A; Kamphuisen HA; Roos RA
    Arch Neurol; 1994 Sep; 51(9):922-8. PubMed ID: 8080393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease.
    Ling H; Massey LA; Lees AJ; Brown P; Day BL
    Brain; 2012 Apr; 135(Pt 4):1141-53. PubMed ID: 22396397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The basis for day and night-time control of symptoms of Parkinson's disease.
    Chaudhuri KR
    Eur J Neurol; 2002 Nov; 9 Suppl 3():40-3. PubMed ID: 12464120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency.
    Louter M; van Sloun RJ; Pevernagie DA; Arends JB; Cluitmans PJ; Bloem BR; Overeem S
    Sleep Med; 2013 Jul; 14(7):668-74. PubMed ID: 23643658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
    Kulua TK; Fedorova NV; Popovkina OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):45-50. PubMed ID: 22027607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Night-time sleep in Parkinson's disease - the potential use of Parkinson's KinetiGraph: a prospective comparative study.
    Klingelhoefer L; Rizos A; Sauerbier A; McGregor S; Martinez-Martin P; Reichmann H; Horne M; Chaudhuri KR
    Eur J Neurol; 2016 Aug; 23(8):1275-88. PubMed ID: 27160044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathophysiology, clinical aspects and therapy of sleep disorders in Parkinson disease].
    Högl B; Wetter TC; Trenkwalder C
    Nervenarzt; 2001 Jun; 72(6):416-24. PubMed ID: 11433700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
    Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
    J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sleep disturbances in Parkinson's disease.
    Comella CL
    Curr Neurol Neurosci Rep; 2003 Mar; 3(2):173-80. PubMed ID: 12583848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease].
    Nodel' MR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):42-7. PubMed ID: 20517225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time structure of leg movement activity during sleep in untreated Parkinson disease and effects of dopaminergic treatment.
    Puligheddu M; Figorilli M; Aricò D; Raggi A; Marrosu F; Ferri R
    Sleep Med; 2014 Jul; 15(7):816-24. PubMed ID: 24891077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease.
    Espay AJ; Giuffrida JP; Chen R; Payne M; Mazzella F; Dunn E; Vaughan JE; Duker AP; Sahay A; Kim SJ; Revilla FJ; Heldman DA
    Mov Disord; 2011 Dec; 26(14):2504-8. PubMed ID: 21953789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls.
    Louter M; Maetzler W; Prinzen J; van Lummel RC; Hobert M; Arends JB; Bloem BR; Streffer J; Berg D; Overeem S; Liepelt-Scarfone I
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):32-7. PubMed ID: 24777169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease?
    Sixel-Döring F; Trautmann E; Mollenhauer B; Trenkwalder C
    Sleep Med; 2012 Oct; 13(9):1178-83. PubMed ID: 22841842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment.
    Mehta SH; Morgan JC; Sethi KD
    CNS Spectr; 2008 Mar; 13(3 Suppl 4):6-11. PubMed ID: 18323761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sleep disorders in Parkinson's disease.
    Stocchi F; Barbato L; Nordera G; Berardelli A; Ruggieri S
    J Neurol; 1998 May; 245 Suppl 1():S15-8. PubMed ID: 9617717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.